Clinical trials recruiting for Neoplasms by Histologic Type
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Atezolizumab | 1 |
| Dabrafenib | 1 |
| Entrectinib | 1 |
| Lutetium [177Lu] oxodotreotide/dotatate | 1 |
| Trametinib | 1 |
Self-screener
Recruiting trials
- DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
- DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
- Spanish Series of Patients Treated With the Radionuclide Lutetium177
Related conditions
Trials recruiting for Neoplasms by Histologic Type often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Neoplasms by Histologic Type trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.